These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6458119)

  • 1. Platelet activation during treadmill exercise in patients with chronic peripheral arterial disease.
    Baele G; Bogaerts H; Clement DL; Pannier R; Barbier F
    Thromb Res; 1981 Aug; 23(3):215-23. PubMed ID: 6458119
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of influence of low-dose acetylsalicylic acid (100 mg daily) on platelet survival time, beta-thromboglobulin and platelet factor 4 in patients with peripheral arterial occlusive disease.
    Minar E; Ehringer H; Jung M; Koppensteiner R; Stümpflen A
    Thromb Res; 1988 Nov; 52(3):219-26. PubMed ID: 2973666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of elevation of beta-thromboglobulin and platelet factor 4 in plasma during exercise in patients with chronic peripheral arterial occlusive disease.
    Minar E; Ehringer H; Schöfl R
    Klin Wochenschr; 1987 May; 65(9):419-23. PubMed ID: 2955158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Determination of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF 4). Detection of an in vivo thrombocyte activation].
    Hellstern P; Köhler M; Wenzel E
    ZFA (Stuttgart); 1981 May; 57(15):1136-41. PubMed ID: 6167083
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between low affinity platelet factor 4 (LA-PF4) and beta-thromboglobulin (beta TG).
    Niewiarowski S
    Thromb Haemost; 1980 Aug; 44(1):47. PubMed ID: 6158765
    [No Abstract]   [Full Text] [Related]  

  • 6. [Lack of effect of low dose acetylsalicylic acid (100 mg/die) on thrombocyte survival and beta-thromboglobulin (beta-TG) and platelet factor 4 (PF 4) in patients with peripheral arterial occlusive disease].
    Minar E; Ehringer H; Jung M; Koppensteiner R; Stümpflen A; Ahmadi R
    Vasa Suppl; 1989; 27():244-6. PubMed ID: 2533741
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion of low-affinity platelet factor 4 to beta-thromboglobulin by plasmin and trypsin.
    Holt JC; Niewiarowski S
    Biochim Biophys Acta; 1980 Oct; 632(2):284-9. PubMed ID: 6158345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial function, platelet activation and coagulation in lower limb occlusive arterial disease during treadmill exercise: correlations with transcutaneous oxygen pressure.
    Constans J; Seigneur M; Blann AD; Lestage B; Resplandy F; Renard M; Chaudet B; Amiral J; Guérin V; Boisseau MR; Conri C
    Thromb Res; 2000 Sep; 99(6):557-61. PubMed ID: 10974340
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence for serotonin binding in vitro by platelet factor 4 and beta-thromboglobulin.
    Heemstra VL
    Thromb Res; 1983 Feb; 29(3):323-32. PubMed ID: 6189240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The relation between erythrocyte filterability and platelet aggregation (in vitro studies in normal subjects and those with vascular disease before and after isotonic exercise)].
    Guerrini M; Vittoria A; Pieragalli D; Acciavatti A; Del Bigo C; Martelli G; Franchi M; Messa G; Galigani C; Di Perri T
    Ric Clin Lab; 1983; 13 Suppl 3():309-14. PubMed ID: 6231712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of acetylsalicylic acid (1.0 g/day) on platelet survival time, beta-thromboglobulin and platelet factor 4 in patients with peripheral arterial occlusive disease.
    Minar E; Ehringer H
    Thromb Res; 1987 Mar; 45(6):791-802. PubMed ID: 2954264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproducibility of platelet survival time measurements in patients with peripheral arterial occlusive disease.
    Minar E; Ehringer H
    Thromb Res; 1987 Oct; 48(1):73-9. PubMed ID: 2962335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet factor 4 and beta thromboglobulin in Moya-Moya disease.
    Albala MM; Levine PH
    Am J Pediatr Hematol Oncol; 1984; 6(1):96-9. PubMed ID: 6201080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemistry, measurement, and clinical significance of platelet specific proteins.
    de Boer AC; Genton E; Turpie AG
    Crit Rev Clin Lab Sci; 1982; 18(2):183-211. PubMed ID: 6185275
    [No Abstract]   [Full Text] [Related]  

  • 15. [Platelet-specific proteins in arteriosclerosis and coronary disease].
    Musiał J
    Kardiol Pol; 1980; 23(8):707-13. PubMed ID: 6158591
    [No Abstract]   [Full Text] [Related]  

  • 16. The release, distribution, and clearance of human beta-thromboglobulin and platelet factor 4.
    Dawes J; Smith RC; Pepper DS
    Thromb Res; 1978 May; 12(5):851-61. PubMed ID: 79232
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma beta-thromboglobulin and platelet factor 4 in renal failure.
    van Hulsteijn H; van Es A; Bertina R; Briët E
    Thromb Res; 1981 Oct 1-15; 24(1-2):175-80. PubMed ID: 6173932
    [No Abstract]   [Full Text] [Related]  

  • 18. [The effect of lysine acetylsalicylate on hemorrheological changes induced through ischemic exertion in patients with vascular disease].
    Vittoria A; Guerrini M; Pieragalli D; Del Bigo C; Martelli G; Franchi M; Messa G; Blardi P; Galigani C; Di Perri T
    Ric Clin Lab; 1983; 13 Suppl 3():315-21. PubMed ID: 6231713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TFP inhibits the expression of the endogenous platelet lectin and secretion of alpha-granules.
    Gartner TK; Walz DA
    Thromb Res; 1983 Jan; 29(1):63-74. PubMed ID: 6188236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.
    Hoet B; Arnout J; Van Geet C; Deckmyn H; Verhaeghe R; Vermylen J
    Thromb Haemost; 1990 Aug; 64(1):87-90. PubMed ID: 2148849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.